Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C11H17N2O3.Ca |
| Molecular Weight | 490.607 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O.CCCC(C)C2(CC)C(=O)NC(=O)[N-]C2=O
InChI
InChIKey=VBJLHIJEIVBIHF-UHFFFAOYSA-L
InChI=1S/2C11H18N2O3.Ca/c2*1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15;/h2*7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;;+2/p-2
Pentobarbital belongs to the class of a short-acting barbiturate is used as sedatives, hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks; preanesthetics and anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Pentobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093872 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PENTOBARBITAL SODIUM Approved UseParenteral
a. Sedatives.
b. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks.
c. Preanesthetics.
d. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Launch Date2016 |
|||
| Primary | PENTOBARBITAL SODIUM Approved UseParenteral
a. Sedatives.
b. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks.
c. Preanesthetics.
d. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Launch Date2016 |
|||
| Primary | PENTOBARBITAL SODIUM Approved UseParenteral
a. Sedatives.
b. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks.
c. Preanesthetics.
d. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Launch Date2016 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.15 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7062221/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PENTOBARBITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7062221/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PENTOBARBITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
50 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7062221/ |
50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PENTOBARBITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Functional characteristics and sites of gene expression of the alpha 1, beta 1, gamma 2-isoform of the rat GABAA receptor. | 1990 Jul |
|
| Luteinizing hormone-releasing hormone neurons express Fos protein during the proestrous surge of luteinizing hormone. | 1990 Jul |
|
| Recovery of costal and crural diaphragmatic contractility from partial paralysis. | 1991 Jul |
|
| Transient expression of progesterone receptor messenger RNA in ovarian granulosa cells after the preovulatory luteinizing hormone surge. | 1991 Jul |
|
| Ethanol sensitivity of the GABAA receptor expressed in Xenopus oocytes requires 8 amino acids contained in the gamma 2L subunit. | 1991 Jul |
|
| GABA/BZ-and NMDA-receptor interaction in digoxin-induced convulsions in rats. | 1991 Jul |
|
| Transient ischemia stimulates glial fibrillary acid protein and vimentin gene expression in the gerbil neocortex, striatum and hippocampus. | 1992 Apr |
|
| Amyloid precursor protein mRNA encoding the Kunitz protease inhibitor domain is increased by kainic acid-induced seizures in rat hippocampus. | 1992 Dec |
|
| Changes of [3H]muscimol binding and GABA(A) receptor beta2-subunit mRNA level by tolerance to and withdrawal from pentobarbital in rats. | 1999 Dec |
|
| GLUT1-deficiency: barbiturates potentiate haploinsufficiency in vitro. | 1999 Dec |
|
| Blockade of glutamate receptors and barbiturate anesthesia: increased sensitivity to pentobarbital-induced anesthesia despite reduced inhibition of AMPA receptors in GluR2 null mutant mice. | 1999 Nov |
|
| The effects of pentobarbital, isoflurane, and propofol on immediate-early gene expression in the vital organs of the rat. | 2000 May |
|
| Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. | 2001 Jun |
|
| Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model. | 2001 Mar |
|
| 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates gonadotropin secretion in the immature female Sprague-Dawley rat through a pentobarbital- and estradiol-sensitive mechanism but does not alter gonadotropin-releasing hormone (GnRH) secretion by immortalized GnRH neurons in vitro. | 2003 Jun |
|
| Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department. | 2003 Nov |
|
| Myoclonus and urinary retention following subarachnoid morphine injection in a dog. | 2003 Oct |
|
| A single M1 residue in the beta2 subunit alters channel gating of GABAA receptor in anesthetic modulation and direct activation. | 2003 Oct 31 |
|
| Key structural features of ligands for activation of human pregnane X receptor. | 2004 Apr |
|
| Contrasting anesthetic sensitivities of T-type Ca2+ channels of reticular thalamic neurons and recombinant Ca(v)3.3 channels. | 2005 Jan |
|
| Effect of N-methyl-D-aspartate receptor epsilon1 subunit gene disruption of the action of general anesthetic drugs in mice. | 2005 Mar |
|
| Changes in expression of GABAA alpha4 subunit mRNA in the brain under anesthesia induced by volatile and intravenous anesthetics. | 2006 Mar |
|
| Effects of isoflurane, pentobarbital, and urethane on apoptosis and apoptotic signal transduction in rat kidney. | 2006 Nov |
|
| [Effects of intravenous anesthetics on acidosis induced apoptosis in primary brain cell culture]. | 2007 Aug |
|
| The lack of CB1 receptors prevents neuroadapatations of both NMDA and GABA(A) receptors after chronic ethanol exposure. | 2007 Aug |
|
| Regulation of mRNA stability through a pentobarbital-responsive element. | 2007 Mar 1 |
|
| Modulation of neuronal activity in CNS pain pathways following propofol administration in rats: Fos and EEG analysis. | 2007 May |
|
| The differential effect of cyclosporine on hypnotic response and pain reaction in mice. | 2007 Nov |
|
| The reduction of tumor necrosis factor-alpha release and tissue damage by pentobarbital in the experimental endotoxemia model. | 2007 Sep |
|
| Microarray analysis of choroid/RPE gene expression in marmoset eyes undergoing changes in ocular growth and refraction. | 2008 Aug 11 |
|
| Targeted deletion of the GABRA2 gene encoding alpha2-subunits of GABA(A) receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates. | 2008 Jul |
|
| Evaluation of atrial fibrillation induced during anesthesia with fentanyl and pentobarbital in German Shepherd Dogs with inherited arrhythmias. | 2008 Nov |
|
| Impact of anesthesia on valvular function in normal rats during echocardiography. | 2008 Oct |
|
| The effectiveness of ethanolic extract of Amaranthus tricolor L.: A natural hepatoprotective agent. | 2010 |
|
| Pentobarbital coma for refractory intra-cranial hypertension after severe traumatic brain injury: mortality predictions and one-year outcomes in 55 patients. | 2010 Aug |
|
| Regulation of cytochrome P450 expression in Drosophila: Genomic insights. | 2010 Jun 1 |
Patents
Sample Use Guides
Intramuscular Administration: IM injection of the sodium salts of barbiturates should be made deeply into a large muscle, and a volume of 5 mL should not be exceeded at any one site because of possible tissue irritation. After IM injection of a hypnotic dose, the patient's vital signs should be monitored. The usual adult dosage of Pentobarbital Sodium is 150 to 200 mg as a single IM injection; the recommended pediatric dosage ranges from 2 to 6 mg/kg as a single IM injection not to exceed 100 mg.
Intravenous Administration: Pentobarbital Sodium should not be admixed with any other medication or solution. IV injection is restricted to conditions in which other routes are not feasible, either because the patient is unconscious (as in cerebral hemorrhage, eclampsia, or status epilepticus), or because the patient resists (as in delirium), or because prompt action is imperative. Slow IV injection is essential, and patients should be carefully observed during administration. This requires that blood pressure, respiration, and cardiac function be maintained, vital signs be recorded, and equipment for resuscitation and artificial ventilation be available. The rate of IV injection should not exceed 50 mg/min for Pentobarbital Sodium. There is no average intravenous dose of Pentobarbital Sodium that can be relied on to produce similar effects in different patients. The possibility of overdose and respiratory depression is remote when the drug is injected slowly in fractional doses. A commonly used initial dose for the 70 kg adult is 100 mg. Proportional reduction in dosage should be made for pediatric or debilitated patients. At least one minute is necessary to determine the full effect of intravenous pentobarbital. If necessary, additional small increments of the drug may be given up to a total of from 200 to 500 mg for normal adults.
Route of Administration:
Other
It was studied the effects of pentobarbital on extracellular activity in ventrobasal thalamic slices. Pentobarbital at sedative-hypnotic concentration (20 microM) reversibly induced 1-15 Hz oscillations. Sustained oscillations required electrical stimulation of internal capsule, but not elevated temperature or low [Mg2+]. Anesthetic concentration (200 microM) of pentobarbital evoked only transient oscillations.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7563-42-0
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
SUB03690MIG
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | |||
|
231-460-2
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | |||
|
100000085545
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | |||
|
66V4W08X7J
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | |||
|
24876-35-5
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | |||
|
m8513
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL448
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY | |||
|
656845
Created by
admin on Sat Dec 16 04:59:39 GMT 2023 , Edited by admin on Sat Dec 16 04:59:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
